Recommendation of the President – Tevimbra (tislelizumab)
On 9 October 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 143/2025 on the reimbursement of the drug Tevimbra (tislelizumab) under drug program B.58 “Treatment of patients with esophageal, gastroesophageal junction, and gastric cancer (ICD-10: C-15-C16)”